Chicago, Illinois 60611


Purpose:

The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the treatment of herpes zoster keratitis. Half the patients will receive the study drug while the other half of the patients will receive the placebo


Study summary:

Patients with herpes zoster keratitis will be enrolled in the study. All patients will receive oral anti-viral medication as a standard-of-care therapy. The patients will be randomized into two groups and given either the study drug or the placebo at the time of enrollment. The patients will come for weekly visits during which slit lamp photograph of the dendrite will be taken. At week 2, if the dendrite has not healed the drug will by unmasked and rescue therapy will be given. the patients will be examined at week 1, 2, and 3 or until resolution occurs.


Criteria:

Inclusion Criteria: - age 18 and above - have not been on gancyclovir gel or any other form of topical antiviral therapy for the past month - able and willing to attend subsequent follow-up visits Exclusion Criteria: - Associated retinitis - patients who are allergic to gancyclovir - patients who will require systemic or intra-vitreal gancyclovir therapy - patients who are pregnant or breastfeeding


NCT ID:

NCT02382588


Primary Contact:

Robert S Feder, MD, MBA
Phone: 312-695-8150
Email: r-feder@northwestern.edu


Backup Contact:

Email: nreinhol@nm.org
Nicole Seddon
Phone: 312-695-0252


Location Contact:

Chicago, Illinois 60611
United States

Robert S Feder, MD, MBA
Phone: 312-695-8150
Email: r-feder@northwestrn.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 24, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.